A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)

Type of Cancer
Lymphoma
Locations
Bethesda
Sponsor
TG Therapeutics, Inc
Protocol Number
UTX-TGR-304
Cancer Diagnosis
To Learn More Call
201-510-0910